CHEPLAPHARM Arzneimittel GmbH

Medical Professionals

Drug Safety & Medical Communications
For Drug Safety and Medical Communications, please contact INTEGRATED THERAPEUTIC SOLUTIONS INC at the number: 1-888-236-5445. (for US market inquiries only)

Product Complaints
Please contact info(at)h2-pharma.com for any product complaint.

Ordering Questions
Please contact orders(at)h2-pharma.com for any ordering question.

Indication

XENICAL is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:

  • adults and pediatric patients aged 12 years and older with obesity
  • adults with overweight in the presence of at least one weight-related comorbid condition

Important Safety Information

XENICAL is contraindicated in patients:

  • chronic malabsorption syndrome
  • cholestasis
  • known hypersensitivity to orlistat or any of the inactive ingredients in XENICAL, serious hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported with XENICAL

Warnings and Precautions:

  • Serious outcomes due to the loss of effect of cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, antiretroviral drugs, certain fat-soluble vitamins, and beta carotene have been reported with coadministration of XENICAL
  • Severe liver injury with hepatocellular necrosis or acute hepatic failure have been reported in patients treated with XENICAL, some cases resulted in liver transplant or death. Instruct patients to report any symptoms of hepatic dysfunction, immediately discontinue if symptoms occur and obtain liver function tests.
  • Monitor renal function in patients at increased risk for oxalate nephropathy. Discontinue XENICAL in patients who develop oxalate nephropathy
  • Acute gallbladder disease has occurred in clinical trials and in postmarketing. If suspected, gallbladder studies and appropriate clinical follow-up are indicated
  • Gastrointestinal events may increase when XENICAL is taken with a diet high in fat (>30% total daily calories from fat), advise patients to adhere to dietary guidelines and distribute the daily intake of fat over three main meals

The most commonly observed adverse events (incidence of ≥5% and twice that of placebo) were oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation and fecal incontinence. In general, the first occurrence of these events was within 3 months of starting therapy.

Report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.
Patients and caregivers may also report side effects to the Safety Call Center at 1-888-236-5445.

CHEPLAPHARM is a family-owned pharmaceutical company, headquartered in Germany. We offer our branded products on a global level. By focusing on an internationally oriented Buy and Build Strategy, we generate annually increasing growth rates. The close collaboration with our business partners and our international subsidiaries allows CHEPLAPHARM to successfully realize its corporate strategy.

H2-Pharma, LLC is a privately owned and operated pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceuticals. H2‐Pharma has the experience and distribution infrastructure to market and distribute products across the spectrum, and do so with a level of personal service that is unmatched in the industry.

Back to top expand_less